Critical reviews in oncology/hematology最新文献_第7页

Metabolic risk factors of colorectal cancer: Umbrella review 结直肠癌的代谢风险因素：综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-06 DOI: 10.1016/j.critrevonc.2024.104502

Meseret Derbew Molla , Erin L. Symonds , Jean M. Winter , Ayal Debie , Molla M. Wassie

{"title":"Metabolic risk factors of colorectal cancer: Umbrella review","authors":"Meseret Derbew Molla , Erin L. Symonds , Jean M. Winter , Ayal Debie , Molla M. Wassie","doi":"10.1016/j.critrevonc.2024.104502","DOIUrl":"10.1016/j.critrevonc.2024.104502","url":null,"abstract":"<div><h3>Background and aim</h3><p>The association between metabolic factors and colorectal cancer (CRC) risk is inconclusive. This umbrella review aimed to summarise and describe the association using existing systematic reviews and/or meta-analyses.</p></div><div><h3>Method</h3><p>Four databases (Medline, Scopus, Web of Science, and Cochrane Library) were searched for systematic reviews and/or meta-analyses of observational studies. Two independent authors extracted data on the summary estimated effect and heterogeneity of studies using I<sup>2</sup> from the individual reviews. The Assessing the Methodological Quality of Systematic Reviews (AMSTAR 2) tool was used to evaluate the methodological quality.</p></div><div><h3>Results</h3><p>49 articles were included in this review. Although most included studies were graded with critically low methodological quality (81.6 %), we found a significant positive association between obesity (summary relative risk (SRR) range 1.19–1.49), diabetes mellitus (SRR range 1.20–1.37), hypertension (SRR range 1.07–1.62), metabolic syndrome (SRR range 1.25–1.36), non-alcoholic fatty liver disease (pooled odds ratio (POR) range 1.13–1.56), and risk of CRC. Higher serum high-density lipoprotein cholesterol levels were associated with a lower risk of CRC in 3/6 reviews, while others did not find any association. There was no clear association between high triglyceride levels, total cholesterol levels, low-density lipoprotein cholesterol levels, and risk of CRC.</p></div><div><h3>Conclusion</h3><p>This umbrella review identified that most metabolic factors are significantly associated with increased risk of CRC. Thus, people affected by metabolic factors may be benefited from CRC screening and surveillance.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104502"},"PeriodicalIF":5.5,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002452/pdfft?md5=653dc1396e4de4bf21fc50492354cfe1&pid=1-s2.0-S1040842824002452-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Facing the climate change: Is radiotherapy as green as we would like? A systematic review 面对气候变化：放射治疗是否如我们所愿是绿色的？系统回顾。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-06 DOI: 10.1016/j.critrevonc.2024.104500

Stefania Volpe , Federico Mastroleo , Maria Giulia Vincini , Mattia Zaffaroni , Alice Porazzi , Ernesto Damiani , Giulia Marvaso , Barbara Alicja Jereczek-Fossa

{"title":"Facing the climate change: Is radiotherapy as green as we would like? A systematic review","authors":"Stefania Volpe , Federico Mastroleo , Maria Giulia Vincini , Mattia Zaffaroni , Alice Porazzi , Ernesto Damiani , Giulia Marvaso , Barbara Alicja Jereczek-Fossa","doi":"10.1016/j.critrevonc.2024.104500","DOIUrl":"10.1016/j.critrevonc.2024.104500","url":null,"abstract":"<div><h3>Purpose</h3><p>To focus on the ecological footprint of radiotherapy (RT), on opportunities for sustainable practices, on future research directions.</p></div><div><h3>Methods</h3><p>Different databases were interrogated using the following terms: Carbon Footprint, Sustainab*, Carbon Dioxide, Radiotherapy, and relative synonyms.</p></div><div><h3>Results</h3><p>931 records were retrieved; 15 reports were included in the review. Eight main thematic areas have been identified. Nine research works analyzed the environmental impact of photon-based external beam RT. Particle therapy was the subject of one work. Other thematic areas were brachytherapy, intra-operative RT, telemedicine, travel-related issues, and the impact of COVID-19.</p></div><div><h3>Conclusion</h3><p>This review demonstrates the strong interest in identifying novel strategies for a more environmentally friendly RT and serves as a clarion call to unveil the environmental impact of carbon footprints entwined with radiation therapy. Future research should address current gaps to guide the transition towards greener practices, reducing the environmental footprint and maintaining high-quality care.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104500"},"PeriodicalIF":5.5,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Minimal residual disease testing for classical Hodgkin lymphoma: A comprehensive review 经典霍奇金淋巴瘤的最小残留病检测：全面回顾。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-06 DOI: 10.1016/j.critrevonc.2024.104503

Momo Arai , Alaa Hamad , Yazan Almasry , Abdullah Alamer , Walid Rasheed , Mahmoud Aljurf , Riad El Fakih

{"title":"Minimal residual disease testing for classical Hodgkin lymphoma: A comprehensive review","authors":"Momo Arai , Alaa Hamad , Yazan Almasry , Abdullah Alamer , Walid Rasheed , Mahmoud Aljurf , Riad El Fakih","doi":"10.1016/j.critrevonc.2024.104503","DOIUrl":"10.1016/j.critrevonc.2024.104503","url":null,"abstract":"<div><p>Classical Hodgkin lymphoma (cHL) is a common lymphoma that affects young patients. Fortunately, the disease is highly curable as it is susceptible to the currently available treatment modalities. Disease monitoring with Positron Emission Tomography and Computed Tomography (PET/ CT) is an integral part of managing these patients. PET guided protocols are currently used to adjust treatment according to the response. The pivotal idea behind the use of response-adapted approaches is to preserve efficacy while decreasing the toxicity. It also helps to intensify therapy in patients in need because of suboptimal response. However, imaging techniques are limited by their sensitivity and specificity. Minimal Residual Disease (MRD) assessment is a newly emerging concept in many hematologic malignancies. It utilizes various molecular techniques such as polymerase chain reaction (PCR), and next-generation sequencing (NGS) as well as flow cytometry, to detect disease traces. This review looks into MRD detection techniques, its current applications, and the evidence in the literature for its use in cHL.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104503"},"PeriodicalIF":5.5,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002464/pdfft?md5=4371b33fcb0e576ca0c101973ded613d&pid=1-s2.0-S1040842824002464-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TIGIT: Will it be the next star therapeutic target like PD-1 in hematological malignancies? TIGIT：在血液恶性肿瘤领域，它是否会像 PD-1 一样成为下一个明星治疗靶点？

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-03 DOI: 10.1016/j.critrevonc.2024.104495

Yang Liu , Wenhui Liu , Tao Wu

引用次数: 0

The emerging role of Artificial Intelligence in proton therapy: A review 人工智能在质子治疗中的新兴作用：综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-09-02 DOI: 10.1016/j.critrevonc.2024.104485

Lars Johannes Isaksson , Federico Mastroleo , Maria Giulia Vincini , Giulia Marvaso , Mattia Zaffaroni , Michał Gola , Giovanni Carlo Mazzola , Luca Bergamaschi , Simona Gaito , Filippo Alongi , Jerome Doyen , Piero Fossati , Karin Haustermans , Morten Høyer , Johannes Albertus Langendijk , Raùl Matute , Ester Orlandi , Marco Schwarz , Esther G.C. Troost , Vladimir Vondracek , Barbara Alicja Jereczek-Fossa

{"title":"The emerging role of Artificial Intelligence in proton therapy: A review","authors":"Lars Johannes Isaksson , Federico Mastroleo , Maria Giulia Vincini , Giulia Marvaso , Mattia Zaffaroni , Michał Gola , Giovanni Carlo Mazzola , Luca Bergamaschi , Simona Gaito , Filippo Alongi , Jerome Doyen , Piero Fossati , Karin Haustermans , Morten Høyer , Johannes Albertus Langendijk , Raùl Matute , Ester Orlandi , Marco Schwarz , Esther G.C. Troost , Vladimir Vondracek , Barbara Alicja Jereczek-Fossa","doi":"10.1016/j.critrevonc.2024.104485","DOIUrl":"10.1016/j.critrevonc.2024.104485","url":null,"abstract":"<div><p>Artificial intelligence (AI) has made a tremendous impact in the space of healthcare, and proton therapy is not an exception. Proton therapy has witnessed growing popularity in oncology over recent decades, and researchers are increasingly looking to develop AI and machine learning tools to aid in various steps of the treatment planning and delivery processes. This review delves into the emergent role of AI in proton therapy, evaluating its development, advantages, intended clinical contexts, and areas of application. Through the analysis of 76 studies, we aim to underscore the importance of AI applications in advancing proton therapy and to highlight their prospective influence on clinical practices.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104485"},"PeriodicalIF":5.5,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Definitive radiotherapy and trismus in HNC patients: A critical review HNC患者的确定性放疗与三联症：评论性综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-27 DOI: 10.1016/j.critrevonc.2024.104486

Orges Spahiu , Cristiano Grossi , Chiara Cavallin , Valeria Chiofalo , Erica Maria Cuffini , Bruna Lo Zito , Francesca Catena , Alessandro Tortarolo , Mario Levis , Maria Grazia Piancino , Umberto Ricardi , Giuseppe Carlo Iorio

{"title":"Definitive radiotherapy and trismus in HNC patients: A critical review","authors":"Orges Spahiu , Cristiano Grossi , Chiara Cavallin , Valeria Chiofalo , Erica Maria Cuffini , Bruna Lo Zito , Francesca Catena , Alessandro Tortarolo , Mario Levis , Maria Grazia Piancino , Umberto Ricardi , Giuseppe Carlo Iorio","doi":"10.1016/j.critrevonc.2024.104486","DOIUrl":"10.1016/j.critrevonc.2024.104486","url":null,"abstract":"<div><h3>Introduction</h3><p>Trismus is a potentially critical morbidity following curative-intended radiotherapy in head and neck cancer patients. However, in this setting, evidence regarding this side effect remains to be fully defined, particularly in terms of dosimetric parameters.</p></div><div><h3>Materials and Methods</h3><p>Key references were derived from a PubMed query. Hand searching and clinicaltrials.gov were also used.</p></div><div><h3>Results</h3><p>This paper contains a narrative report and a critical discussion of the evidence on radiation-induced trismus in the literature, particularly the dosimetric concerns.</p></div><div><h3>Conclusions</h3><p>The treatment goal should be to maintain high cure rates and limit the onset of complications. Further evaluations of dosimetric measures and clinical outcomes are warranted to identify patients at higher risk to target treatment tailoring.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"203 ","pages":"Article 104486"},"PeriodicalIF":5.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142094315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review 线粒体在 BRAF 突变癌症中的作用和线粒体靶向疗法的潜力：综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-26 DOI: 10.1016/j.critrevonc.2024.104484

Yanyan Gao , Hua Zheng

{"title":"Role of mitochondria and potential of mitochondria-targeted therapy in BRAF mutant cancer: A review","authors":"Yanyan Gao , Hua Zheng","doi":"10.1016/j.critrevonc.2024.104484","DOIUrl":"10.1016/j.critrevonc.2024.104484","url":null,"abstract":"<div><p>The classical mitogen-activated protein kinase (MAPK) signaling pathway, the Ras/Raf/MEK (mitogen-activated protein kinase/ERK kinase)/ERK protein kinase cascade, is a conserved cascade that regulates cell growth, differentiation, and proliferation. The significance of BRAF in cancer was established with the discovery of cancer-activating mutations in <em>BRAF</em> in several human tumors in 2002. Currently, <em>BRAF</em> is recognized as a driver mutation that affects cancer phenotypes in different ways, making it an important therapeutic target for cancer. BRAF-selective inhibitors have shown promise in clinical trials involving patients with metastatic melanoma. However, resistance mechanisms to BRAF inhibitors therapy have resulted in short-lived therapeutic responses. Further in-depth research is imperative to explore resistance mechanisms that oppose the effectiveness of BRAF inhibitors. Metabolic reprogramming has emerging role in <em>BRAF-</em>mutant cancers. In particular, mitochondrial metabolism and its closely related signaling pathways mediated by mitochondria have become recognized as potential new targets for treating <em>BRAF</em>-mutant cancers. This review, examines the progress in understanding <em>BRAF</em> mutations in cancer, the clinicopathological correlation of BRAF inhibitors, and recent advances in mitochondrial metabolism, mitochondrial dynamics and mitochondrial mediated death in <em>BRAF</em>-mutant cancer. This review will inform future cancer research and lay the foundation for novel treatment combinations of <em>BRAF</em>-mutant cancers.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"203 ","pages":"Article 104484"},"PeriodicalIF":5.5,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142094316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic interactions of host-gut microbiota: New possibilities for the precise diagnosis and therapeutic discovery of gastrointestinal cancer in the future—A review 宿主-肠道微生物群的代谢相互作用：未来胃肠癌精确诊断和治疗发现的新可能性--综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-21 DOI: 10.1016/j.critrevonc.2024.104480

Jianing Yu , Lu Li , Xufeng Tao , Yanwei Chen , Deshi Dong

{"title":"Metabolic interactions of host-gut microbiota: New possibilities for the precise diagnosis and therapeutic discovery of gastrointestinal cancer in the future—A review","authors":"Jianing Yu , Lu Li , Xufeng Tao , Yanwei Chen , Deshi Dong","doi":"10.1016/j.critrevonc.2024.104480","DOIUrl":"10.1016/j.critrevonc.2024.104480","url":null,"abstract":"<div><p>Gastrointestinal (GI) cancer continues to pose a significant global health challenge. Recent advances in our understanding of the complex relationship between the host and gut microbiota have shed light on the critical role of metabolic interactions in the pathogenesis and progression of GI cancer. In this study, we examined how microbiota interact with the host to influence signalling pathways that impact the formation of GI tumours. Additionally, we investigated the potential therapeutic approach of manipulating GI microbiota for use in clinical settings. Revealing the complex molecular exchanges between the host and gut microbiota facilitates a deeper understanding of the underlying mechanisms that drive cancer development. Metabolic interactions hold promise for the identification of microbial signatures or metabolic pathways associated with specific stages of cancer. Hence, this study provides potential strategies for the diagnosis, treatment and management of GI cancers to improve patient outcomes.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"203 ","pages":"Article 104480"},"PeriodicalIF":5.5,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002233/pdfft?md5=e378dde927ed1525a75d01f0adff38bb&pid=1-s2.0-S1040842824002233-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors 揭示循环肿瘤细胞的影响：二十年来实体瘤的发现与临床进展。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-17 DOI: 10.1016/j.critrevonc.2024.104483

Carolina Reduzzi , Eleonora Nicolo’ , Surbhi Singhal , Konstantinos Venetis , Ana Ortega-Franco , Diego de Miguel-Perez , Angelo Dipasquale , Mohamed A. Gouda , Erick F. Saldanha , Pashtoon M. Kasi , Eloisa Jantus-Lewintre , Nicola Fusco , Umberto Malapelle , David R. Gandara , Christian Rolfo , Maria Jose Serrano , Massimo Cristofanilli , On behalf of the International Society of Liquid Biopsy (ISLB)

{"title":"Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors","authors":"Carolina Reduzzi , Eleonora Nicolo’ , Surbhi Singhal , Konstantinos Venetis , Ana Ortega-Franco , Diego de Miguel-Perez , Angelo Dipasquale , Mohamed A. Gouda , Erick F. Saldanha , Pashtoon M. Kasi , Eloisa Jantus-Lewintre , Nicola Fusco , Umberto Malapelle , David R. Gandara , Christian Rolfo , Maria Jose Serrano , Massimo Cristofanilli , On behalf of the International Society of Liquid Biopsy (ISLB)","doi":"10.1016/j.critrevonc.2024.104483","DOIUrl":"10.1016/j.critrevonc.2024.104483","url":null,"abstract":"<div><p>Circulating tumor cells (CTCs) enumeration and molecular profiling hold promise in revolutionizing the management of solid tumors. Their understanding has evolved significantly over the past two decades, encompassing pivotal biological discoveries and clinical studies across various malignancies. While for some tumor types, such as breast, prostate, and colorectal cancer, CTCs are ready to enter clinical practice, for others, additional research is required. CTCs serve as versatile biomarkers, offering insights into tumor biology, metastatic progression, and treatment response. This review summarizes the latest advancements in CTC research and highlights future directions of investigation. Special attention is given to concurrent evaluations of CTCs and other circulating biomarkers, particularly circulating tumor DNA. Multi-analyte assessment holds the potential to unlock the full clinical capabilities of liquid biopsy. In conclusion, CTCs represent a transformative biomarker in precision oncology, offering extraordinary opportunities to translate scientific discoveries into tangible improvements in patient care.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"203 ","pages":"Article 104483"},"PeriodicalIF":5.5,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142006171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unleashing precision: A review of targeted approaches in pleural mesothelioma 释放精准：胸膜间皮瘤靶向治疗方法综述。

IF 5.5 2区医学

Critical reviews in oncology/hematology Pub Date : 2024-08-17 DOI: 10.1016/j.critrevonc.2024.104481

Mario Occhipinti , Marta Brambilla , Raimondo Di Liello , Paolo Ambrosini , Lorenzo Lobianco , Rita Leporati , Maria Salvarezza , Fabiana Vitiello , Silvia Marchesi , Sara Manglaviti , Teresa Beninato , Laura Mazzeo , Claudia Proto , Arsela Prelaj , Roberto Ferrara , Carminia Maria Della Corte , Giuseppe Lo Russo , Filippo de Braud , Monica Ganzinelli , Giuseppe Viscardi

{"title":"Unleashing precision: A review of targeted approaches in pleural mesothelioma","authors":"Mario Occhipinti , Marta Brambilla , Raimondo Di Liello , Paolo Ambrosini , Lorenzo Lobianco , Rita Leporati , Maria Salvarezza , Fabiana Vitiello , Silvia Marchesi , Sara Manglaviti , Teresa Beninato , Laura Mazzeo , Claudia Proto , Arsela Prelaj , Roberto Ferrara , Carminia Maria Della Corte , Giuseppe Lo Russo , Filippo de Braud , Monica Ganzinelli , Giuseppe Viscardi","doi":"10.1016/j.critrevonc.2024.104481","DOIUrl":"10.1016/j.critrevonc.2024.104481","url":null,"abstract":"<div><p>This review delves into the intricate landscape of pleural mesothelioma (PM), emphasizing the need for nuanced therapeutic strategies. While platinum-based chemotherapy remains a cornerstone, the advent of immune checkpoint inhibitors (ICIs), notably through the Checkmate 743 trial, has reshaped treatment paradigms. Challenges persist due to patient heterogeneity and a lack of specific biomarkers. Targeting genotypic and phenotypic alterations emerges as a promising avenue, demanding precision oncology in this rare disease. CDKN2A loss, prevalent in PM, may respond to CDK4/6 inhibitors. Defects in MMR and HR suggest tailored approaches with ICI or PARP inhibitors, respectively. Ongoing trials explore novel inhibitors and promising targets like mesothelin. Implementing these strategies requires overcoming challenges in patient selection, combination therapies, biomarker identification, and cost considerations. Collaboration is crucial for transforming these insights into impactful clinical interventions, heralding the era of personalized and precision medicine for PM.</p></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"203 ","pages":"Article 104481"},"PeriodicalIF":5.5,"publicationDate":"2024-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002245/pdfft?md5=f6fadf11ec995d4ff3fcd3e839a5dc32&pid=1-s2.0-S1040842824002245-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142006170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0